70 related articles for article (PubMed ID: 15225780)
1. Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells.
Gommersall LM; Khanim FL; Peehl DM; Doherty AH; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):251-6. PubMed ID: 15225780
[TBL] [Abstract][Full Text] [Related]
2. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic corruption of VDR signalling in malignancy.
Abedin SA; Banwell CM; Colston KW; Carlberg C; Campbell MJ
Anticancer Res; 2006; 26(4A):2557-66. PubMed ID: 16886664
[TBL] [Abstract][Full Text] [Related]
4. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
5. Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors.
Banwell CM; O'Neill LP; Uskokovic MR; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):245-9. PubMed ID: 15225779
[TBL] [Abstract][Full Text] [Related]
6. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009
[TBL] [Abstract][Full Text] [Related]
7. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.
Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG
Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
[TBL] [Abstract][Full Text] [Related]
11. Identification of VDR-responsive gene signatures in breast cancer cells.
Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ
Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416
[TBL] [Abstract][Full Text] [Related]
12. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
Essa S; Reichrath S; Mahlknecht U; Montenarh M; Vogt T; Reichrath J
Anticancer Res; 2012 Jan; 32(1):383-9. PubMed ID: 22213330
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
[TBL] [Abstract][Full Text] [Related]
14. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer.
Nakagawa K; Kawaura A; Kato S; Takeda E; Okano T
Carcinogenesis; 2005 Feb; 26(2):429-40. PubMed ID: 15539405
[TBL] [Abstract][Full Text] [Related]
15. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth.
Qiao S; Tuohimaa P
Biochem Biophys Res Commun; 2004 Jun; 319(2):358-68. PubMed ID: 15178414
[TBL] [Abstract][Full Text] [Related]
16. MAPK inhibition by 1alpha,25(OH)2-Vitamin D3 in breast cancer cells. Evidence on the participation of the VDR and Src.
Rossi AM; Capiati DA; Picotto G; Benassati S; Boland RL
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):287-90. PubMed ID: 15225787
[TBL] [Abstract][Full Text] [Related]
17. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis.
Peehl DM; Shinghal R; Nonn L; Seto E; Krishnan AV; Brooks JD; Feldman D
J Steroid Biochem Mol Biol; 2004 Oct; 92(3):131-41. PubMed ID: 15555907
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells.
Lambert JR; Young CD; Persons KS; Ray R
Biochem Biophys Res Commun; 2007 Sep; 361(1):189-95. PubMed ID: 17658477
[TBL] [Abstract][Full Text] [Related]
20. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro.
Seifert M; Rech M; Meineke V; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):375-9. PubMed ID: 15225804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
